Yu, Xiaojie
James, Sonya
Felce, James H.
Kellermayer, Blanka
Johnston, David A.
Chan, H. T. Claude
Penfold, Christine A.
Kim, Jinny
Inzhelevskaya, Tatyana
Mockridge, C. Ian
Watanabe, Yasunori
Crispin, Max http://orcid.org/0000-0002-1072-2694
French, Ruth R.
Duriez, Patrick J.
Douglas, Leon R.
Glennie, Martin J.
Cragg, Mark S. http://orcid.org/0000-0003-2077-089X
Article History
Received: 5 February 2021
Accepted: 4 June 2021
First Online: 23 June 2021
Competing interests
: Mark S. Cragg acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent and has received research funding from BioInvent, GSK, UCB, iTeos, and Roche. Martin J. Glennie acts as a consultant to a number of biotech companies and receives institutional payments and royalties from antibody patents and licences. This work is related to patent Family WO 2015/145360 protecting antibodies containing modified hIgG2 domains which elicit agonist or antagonistic properties.